CQ Roll Call Policy and Politics
Copycat Drugs Raise The Question: What’s In a Name?
November 09, 2015
An estimated $60 billion worth of biotechnology drugs will lose patent protection next year and the Food and Drug Administration and the government’s top consumer watchdog agency can’t seem to agree on what to name cheaper, copycat versions. That could complicate efforts to hold down medical spending.
CQ Roll Call Policy and Politics
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!